{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:05:36Z","timestamp":1782536736141,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK100928"],"award-info":[{"award-number":["U01DK100928"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10620-017-4812-7","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T11:51:52Z","timestamp":1510141912000},"page":"3596-3604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Identification and Characterization of Fenofibrate-Induced Liver Injury"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1384-2349","authenticated-orcid":false,"given":"Jawad","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiman","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T.","family":"Cirulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Hoofnagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"4812_CR1","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0002-9149(96)00159-2","volume":"77","author":"G Assmann","year":"1996","unstructured":"Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179.","journal-title":"Am J Cardiol"},{"key":"4812_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","volume":"374","author":"FE Dewey","year":"2016","unstructured":"Dewey FE, Gusarova V, O\u2019Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374:1123.","journal-title":"N Engl J Med"},{"key":"4812_CR3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","volume":"374","author":"Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators","year":"2016","unstructured":"Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med.. 2016;374:1134.","journal-title":"N Engl J Med."},{"key":"4812_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1.","journal-title":"Circulation"},{"key":"4812_CR5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849.","journal-title":"Lancet"},{"key":"4812_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jama.2011.353","volume":"305","author":"CA Jackevicius","year":"2011","unstructured":"Jackevicius CA, Tu JV, Ross JS, et al. Use of fibrates in the United States and Canada. JAMA. 2011;305:1217\u20131224.","journal-title":"JAMA"},{"key":"4812_CR7","first-page":"525","volume":"22","author":"N Ganne-Carri\u00e9","year":"1998","unstructured":"Ganne-Carri\u00e9 N, de Leusse A, Guettier C, et al. Autoimmune hepatitis induced by fibrates. Gastroenterol Clin Biol. 1998;22:525\u2013529.","journal-title":"Gastroenterol Clin Biol"},{"key":"4812_CR8","doi-asserted-by":"publisher","first-page":"7702","DOI":"10.3748\/wjg.v11.i48.7702","volume":"11","author":"K Dohmen","year":"2005","unstructured":"Dohmen K, Wen CY, Nagaoka S, et al. Fenofibrate-induced\u00a0liver\u00a0injury. World J Gastroenterol. 2005;11:7702\u20137703.","journal-title":"World J Gastroenterol"},{"key":"4812_CR9","first-page":"5244","volume":"12","author":"MI Lucena","year":"2006","unstructured":"Lucena MI, Andrade RJ, Vicioso L, et al. Prolonged cholestasis after raloxifene and\u00a0fenofibrate\u00a0interaction: a case report. World J Gastroenterol. 2006;12:5244\u20135246.","journal-title":"World J Gastroenterol"},{"key":"4812_CR10","first-page":"245","volume":"67","author":"CY Ho","year":"2004","unstructured":"Ho CY, Kuo TH, Chen TS, et al. Fenofibrate-induced acute cholestatic hepatitis. J Chin Med Assoc. 2004;67:245\u2013247.","journal-title":"J Chin Med Assoc"},{"key":"4812_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2710.2009.01029.x","volume":"34","author":"D Hajdu","year":"2009","unstructured":"Hajdu D, Aiglov\u00e1 K, Vinklerov\u00e1 I, et al. Acute\u00a0cholestatic\u00a0hepatitis induced by fenofibrate. J Clin Pharm Ther. 2009;34:599\u2013602.","journal-title":"J Clin Pharm Ther"},{"key":"4812_CR12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","volume":"56","author":"A Rodr\u00edguez-Vilarrupla","year":"2012","unstructured":"Rodr\u00edguez-Vilarrupla A, Lavi\u00f1a B, Garc\u00eda-Calder\u00f3 H, et al. PPAR\u03b1 activation improves endothelial dysfunction and reduces\u00a0fibrosis\u00a0and portal pressure in cirrhotic rats. J Hepatol. 2012;56:1033\u20131039.","journal-title":"J Hepatol"},{"key":"4812_CR13","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","volume":"65","author":"A Montagner","year":"2016","unstructured":"Montagner A, Polizzi A, Fouch\u00e9 E, et al. Liver\u00a0PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut. 2016;65:1202\u20131214.","journal-title":"Gut"},{"key":"4812_CR14","doi-asserted-by":"publisher","unstructured":"Hegade VS, Khanna A, Walker LJ, et al. Long-term\u00a0fenofibrate\u00a0treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC\u00a0risk score. Dig Dis Sci. doi:10.1007\/s10620-016-4250-y. 2016 Jul 19. [Epub ahead of print].","DOI":"10.1007\/s10620-016-4250-y"},{"key":"4812_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/apt.13465","volume":"43","author":"AC Cheung","year":"2016","unstructured":"Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and\u00a0fenofibrate\u00a0in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016;43:283\u2013293.","journal-title":"Aliment Pharmacol Ther"},{"key":"4812_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, et al. Causality\u00a0assessment\u00a0in\u00a0drug-induced liver injury\u00a0using a\u00a0structured\u00a0expert opinion\u00a0process:\u00a0comparison\u00a0to the\u00a0Roussel\u2013Uclaf\u00a0causality\u00a0assessment\u00a0method. Hepatology. 2010;51:2117\u20132126.","journal-title":"Hepatology"},{"key":"4812_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","volume":"46","author":"C Benichou","year":"1993","unstructured":"Benichou C, Danan G, Flahault A. Causality\u00a0assessment\u00a0of\u00a0adverse\u00a0reactions to\u00a0drugs\u2013II. An\u00a0original\u00a0model\u00a0for\u00a0validation\u00a0of\u00a0drug\u00a0causalityassessment\u00a0methods:\u00a0case reports\u00a0with\u00a0positive\u00a0rechallenge. J Clin Epidemiol. 1993;46:1331\u20131336.","journal-title":"J Clin Epidemiol"},{"key":"4812_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf.. 2009;32:55\u201368.","journal-title":"Drug Saf."},{"key":"4812_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.26709","volume":"59","author":"DE Kleiner","year":"2014","unstructured":"Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected\u00a0drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661\u2013670.","journal-title":"Hepatology"},{"key":"4812_CR20","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/ajg.2015.283","volume":"110","author":"RJ Fontana","year":"2015","unstructured":"Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450\u20131459.","journal-title":"Am J Gastroenterol"},{"key":"4812_CR21","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340\u20131352.","journal-title":"Gastroenterology"},{"key":"4812_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","volume":"152","author":"P Nicoletti","year":"2017","unstructured":"Nicoletti P, Aithal GP, Bjornsson ES, et al. Association of liver injury from specific drugs, or groups of\u00a0drugs, with polymorphisms in HLA and other genes in a\u00a0Genome-Wide Association study. Gastroenterology. 2017;152:1078\u20131089.","journal-title":"Gastroenterology"},{"key":"4812_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hep.25645","volume":"56","author":"AD Patterson","year":"2012","unstructured":"Patterson AD, Shah YM, Matsubara T, et al. Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced\u00a0liver\u00a0toxicity. Hepatology. 2012;56:281\u2013290.","journal-title":"Hepatology"},{"key":"4812_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/j.gastro.2011.09.051","volume":"142","author":"T Moustafa","year":"2012","unstructured":"Moustafa T, Fickert P, Magnes C, et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic\u00a0liver\u00a0injury. Gastroenterology. 2012;142:140\u2013151.","journal-title":"Gastroenterology"},{"key":"4812_CR25","unstructured":"https:\/\/livertox.nih.gov. Accessed 2 May 2017."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-017-4812-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4812-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4812-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T08:59:50Z","timestamp":1659085190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-017-4812-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["4812"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4812-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]},"assertion":[{"value":"25 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Chalasani has ongoing consulting activities (or had in the preceding 12\u00a0months) with NuSirt, Abbvie, Eli Lilly, Afimmune (DS Biopharma), Tobira (Allergan), Madrigal, Shire, Cempra, Ardelyx, Gen Fit and Amarin. These consulting activities are generally in the areas of nonalcoholic fatty liver disease and drug hepatotoxicity. Dr. Chalasani receives research grant support from Intercept, Lilly, Gilead, Galectin Therapeutics and Cumberland where his institution receives the funding. Over the last decade, Dr. Chalasani has served as a paid consultant to more than 30 pharmaceutical companies, and these outside activities have regularly been disclosed to his institutional authorities. Drs. Kleiner and Hoofnagle have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}